Topics
Podcast
Magazine
Popular Tags
More
Disease foundations that use a venture capital model get a stake in the breakthroughs they fund. Not everyone thinks that’s a good idea.
Physicians routinely prescribe drugs for uses not approved by the FDA. But should drug reps be allowed to tout those uses?
“Large molecule” therapies, tailored to home in on otherwise untreatable ills, have become medicine’s hottest commodity.
Who will be the first to tap the potential of brown fat?
Drug availability is getting worse, with essential medicines often impossible to obtain. What will it take to fix the system?
Zinc fingers could pull gene therapy back from the brink—but only if more researchers can get their hands on the remarkable proteins.
When proteins misfold, molecular chaos ensues, leading to cystic fibrosis and other ills. New research aims to unwind the mistakes.
Handouts from drug companies might seem helpful, but some experts contend that they create conflicts of interest and raise prescription costs.
A movement to ban uncredited contributors is growing among medical journals.
The protein endothelin shows up everywhere, so scientists hoped blocking its action could treat many diseases. It hasn’t happened—yet.
No Articles Found.
We use cookies and other tools to enhance your experience on our website and to analyze our web traffic. For more information about these cookies and the data collected, please refer to our Privacy Policy.
